Antengene Corporation Co., Ltd. – Trademark Portfolio
Entity Type: 99
Antengene Corporation Co., Ltd. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include ANTENGENE and ANTENNOVA.
Room 703, Comprehensive Building,
Kechuang Park, No. 398 Mahuan Rd, Yuecheng District, Shaoxing City 455112 Zhejiang Province
Showing of trademarks Trademarks
Trademark Classifications
Antengene Corporation Co., Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Antengene Corporation Co., Ltd. have?
Antengene Corporation Co., Ltd. has 5 U.S. trademarks filed with the USPTO. Of these, 5 registered.
What trademark classes does Antengene Corporation Co., Ltd. file in?
Antengene Corporation Co., Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Antengene Corporation Co., Ltd.'s most well-known trademarks?
Antengene Corporation Co., Ltd.'s registered trademark portfolio includes well-known marks such as ANTENGENE and ANTENNOVA. These are among 5 currently registered trademarks in the portfolio.
What is Antengene Corporation Co., Ltd.'s trademark registration success rate?
Antengene Corporation Co., Ltd. has a 100% trademark registration rate, with 5 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.